Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Apatinib plus
Camrelizumab combined with docetaxel and S-1 as the first-line treatment of metastatic
adenocarcinoma of gastric and gastroesophageal junction.
Phase:
Phase 2
Details
Lead Sponsor:
Zhou Fuxiang
Collaborators:
Henan Provincial People's Hospital Huangshi Central Hospital Huangshi Central Hospital, China Hubei Cancer Hospital